MedTrace Logo

Usefulness of Non TNF Usage in RA Patients

NCT03784261 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-09-21

No results posted yet for this study

Summary

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients:

1. Sarilumab treatment for 12 months
2. Tocilizmab treatment for 12 months
3. Abatacept treatment for 12 months

Conditions

Interventions

DRUG

Drug: "Salirumab"

To examine the effects of salirumab in RA patients

DRUG

Drug: "Tocilizmab"

To examine the effects of tocilizmab in RA patients

DRUG

Drug: "Abatacept"

To examine the effects of abatacept in RA patients

Sponsors & Collaborators

  • Shinshu University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-17
Primary Completion
2022-12-16
Completion
2024-12-16

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03784261 on ClinicalTrials.gov